Comparative Pharmacology
Head-to-head clinical analysis: JANUMET XR versus LINAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET XR versus LINAGLIPTIN.
JANUMET XR vs LINAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JANUMET XR is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases active incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
One tablet orally once daily, with evening meal; initial dose based on patient's current sitagliptin and metformin doses, or new patients: starting dose 50 mg sitagliptin/500 mg metformin XR; maximum dose 100 mg sitagliptin/2000 mg metformin XR per day.
5 mg orally once daily
None Documented
None Documented
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Sitagliptin: terminal half-life ~12.4 hours, allowing once-daily dosing. Metformin: terminal half-life ~6.2 hours in plasma, increased to ~17.6 hours in renal impairment.
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Sitagliptin: ~79% excreted unchanged in urine via renal tubular secretion (active secretion) and glomerular filtration; ~13% undergoes hepatic metabolism; ~1% excreted in feces. Metformin: ~90% excreted unchanged in urine via active tubular secretion.
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."